Effects of KRT17 regulating Wnt/β-catenin signaling pathway on proliferation, apoptosis and epithelial mesenchymal transformation of bladder cancer cells

doi:10.11958/20241498

Abstract

Abstract:

Objective To investigate the impacts of knocking-down Keratin 17 (KRT17) on proliferation, apoptosis and epithelial mesenchymal transition (EMT) of bladder cancer cells by regulating Wnt/β-catenin signaling pathway. Methods The expression of KRT17 mRNA and protein in bladder cancer tissue, adjacent tissue, bladder cancer cell lines (5637, T24 and UM-UC-3) and human immortalized urothelial cell line SV-HUC-1 were detected by qRT-PCR and Western blot assay. Immunohistochemical staining was used to detect the expression of KRT17 in the tissues.Cells transfected with NC siRNA and KRT17 siRNA were labeled as the NC siRNA group and the KRT17 siRNA group, respectively. T24 cells treated with 20 mmol/L LiCl were labeled as the LiCl group. T24 cells transfected with KRT17 siRNA and treated with 20 mmol/L LiCl were labeled as the KRT17 siRNA+LiCl group. The non transfected cells were used as the blank group. CCK-8, cloning formation experiment and flow cytometry were applied to detect cell proliferation and apoptosis. QRT-PCR was applied to detect KRT17 mRNA expression. Western blot assay was applied to detect the expression levels of KRT17, β-catenin, Cyclin D1, EMT related proteins Vimentin, E-cadherin and Snail1 proteins. Results The expression of KRT17 mRNA and protein was greatly increased in bladder cancer tissue and cells (P<0.05). The cell proliferation, colony count, KRT17 mRNA and protein expression, β-catenin, Cyclin D1, Vimentin, and Snail expression were lower in the KRT17 siRNA group than those in the NC siRNA group and the blank group, while apoptosis and E-cadherin expression were higher (P<0.05). LiCl reversed the inhibition of KRT17 knockdown on the malignant behavior of bladder cancer. Conclusion Knocking-down KRT17 inhibits the proliferation and EMT of bladder cancer cells and promotes their apoptosis by inhibiting Wnt/β-catenin signaling pathway.

Key words: urinary bladder neoplasms, epithelial-mesenchymal transition, cell proliferation, apoptosis, KRT17, Wnt/β-catenin signaling pathway

CLC Number:

R737.14

Figures/Tables 14

References 22

[1]	CHEN W, ZHAO S, YU W, et al. SC66 inhibits the proliferation and induces apoptosis of human bladder cancer cells by targeting the AKT/β-catenin pathway[J]. J Cell Mol Med, 2021, 25(22):10684-10697. doi:10.1111/jcmm.17005.
[2]	吴潇芸, 吴林秀, 张丽娣, 等. LINC00839靶向调控miR-124-3p对膀胱癌细胞生物学行为的影响[J]. 天津医药, 2023, 51(5):464-468.
	WU X Y, WU L X, ZHANG L D, et al. Effect of LINC00839 on biological behavior of bladder cancer cells by targeting miR-124-3p[J]. Tianjin Med J, 2019, 51(5):464-468. doi:10.11958/20221488.
[3]	SU Y, FENG W, SHI J, et al. circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway[J]. Mol Cancer, 2020, 19(1):23-37. doi:10.1186/s12943-020-01284-5.
[4]	洪翔, 顾晓露. 根治性全膀胱切除加回肠代膀胱术不同手术方式的疗效比较[J]. 中国基层医药, 2022, 29(1):96-100.
	HONG X, GU X L. Efficacy of different surgical methods for radical cystectomy plus Bricker's ileal conduit urinary diversion[J]. Chinese Journal of Primary Medicine and Pharmacy, 2022, 29(1):96-100. doi:10.3760/cma.j.issn.1008-6706.2022.01.020.
[5]	王雪梅, 程玉, 齐洁敏. PRMT7通过调控Notch信号转导通路抑制膀胱癌细胞增殖和迁移[J]. 中国癌症杂志, 2023, 33(5):437-444.
	WANG X M, CHENG Y, QI J M. PRMT7 inhibits the proliferation and migration of bladder cancer cells by regulating Notch signaling pathway[J]. Chin J Cancer, 2023, 33(5):437-444. doi:10.19401/j.cnki.1007-3639.
[6]	LI C, TENG Y, WU J, et al. A pan-cancer analysis of the oncogenic role of Keratin 17 (KRT17) in human tumors[J]. Transl Cancer Res, 2021, 10(10):4489-4501. doi:10.21037/tcr-21-2118.
[7]	LI C, SU H, RUAN C, et al. Keratin 17 knockdown suppressed malignancy and cisplatin tolerance of bladder cancer cells,as well as the activation of AKT and ERK pathway[J]. Folia Histochem Cytobiol, 2021, 59(1):40-48. doi:10.5603/FHC.a2021.0005.
[8]	WANG X, LUO L, XU J, et al. Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/β-catenin pathways[J]. Genes Dis, 2023, 11(2):1050-1065. doi:10.1016/j.gendis.2023.03.031.
[9]	ZHANG J, LI Q, SUN Q, et al. Epigenetic modifications inhibit the expression of MARVELD1 and in turn tumorigenesis by regulating the Wnt/β-catenin pathway in pan-cancer[J]. J Cancer, 2022, 13(1):225-242. doi:10.7150/jca.63608.
[10]	左明顺, 董志诚, 左玉, 等. 蒲公英抗膀胱癌潜在机制的研究进[J]. 中国实验方剂学杂志, 2024, 30(7):290-298.
	ZUO M S, DONG Z C, ZUO Y, et al. Potential mechanism of Taraxaci Herba against bladder cancer:a review[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2024, 30(7):290-298. doi:10.13422/j.cnki.syfjx.20231124.
[11]	ZHOU Q, YU J, ZHENG Q, et al. Kinesin family member 3A stimulates cell proliferation,migration,and invasion of bladder cancer cells in vitro and in vivo[J]. FEBS Open Bio, 2021, 11(5):1487-1496. doi:10.1002/2211-5463.12768.
[12]	ZHANG H, ZHANG Y, FENG Z, et al. Analysis of the expression and role of Keratin 17 in human tumors[J]. Front Genet, 2022, 13(1):801698-801712. doi:10.3389/fgene.2022.801698.
[13]	张晓峰, 宋芳, 朱林忠. 局部晚期宫颈癌患者血清KRT17蛋白表达水平对动脉介入新辅助化疗效果的影响[J]. 癌变·畸变·突变, 2024, 36(2):112-117.
	ZHANG X F, SONG F, ZHU L Z. Influence of serum KRT17 protein expression level on the effect of neoadjuvant chemotherapy after arterial intervention in patients with local advanced cervical cancer[J]. Canceration Aberration and Mutation, 2024, 36(2):112-117. doi:10.3969/j.issn.1004-616x.2024.02.00.
[14]	DAYATI P, SHAKHSSALIM N, ALLAMEH A. Over-expression of KRT17 and MDK genes at mRNA levels in urine-exfoliated cells is associated with early non-invasive diagnosis of non-muscle-invasive bladder cancer[J]. Clin Biochem, 2024, 26(1):110808-110820. doi:10.1016/j.clinbiochem.2024.110808.
[15]	LIU B, DAN W, WEI Y, et al. β-asarone inhibits the migration,invasion,and EMT of bladder cancer through activating ER stress[J]. Cancer Med, 2023, 12(12):13610-13622. doi:10.1002/cam4.6059.
[16]	徐兵, 李勇, 刘明, 等. 沉默TRIM31基因表达通过调控Wnt/β‑catenin信号通路抑制膀胱癌细胞的迁移与侵袭[J]. 中国免疫学杂志, 2021, 37(15):1836-1840.
	XU B, LI Y, LIU M, et al. Silencing TRIM31 gene expression inhibits the migration and invasion of bladder cancer cells by regulating Wnt/β-catenin signaling pathway[J]. Chin J Immun, 2021, 37(15):1836-1840. doi:10.3969/j.issn.1000-484X.2021.15.009.
[17]	BABU S, KIM N W, WU M, et al. Keratin 17 is a novel cytologic biomarker for urothelial carcinoma diagnosis[J]. Am J Clin Pathol, 2021, 156(5):926-933. doi:10.1093/ajcp/aqab050.
[18]	KOTOLLOSHI R, GAJDA M, GRIMM M O, et al. Wnt/β-Catenin signalling and its cofactor BCL9L have an oncogenic effect in bladder cancer cells[J]. Int J Mol Sci, 2022, 23(10):5319-5336. doi:10.3390/ijms23105319.
[19]	HUANG Z, GAO H, QING L, et al. A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/β‑catenin signaling pathway[J]. PeerJ, 2022, 10(1):e13220. doi:10.7717/peerj.13220.
[20]	WU L, DING W, WANG X, et al. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/β-catenin signaling pathway[J]. Genes Genomics, 2023, 45(10):1329-1338. doi:10.1007/s13258-023-01437-y.
[21]	LI Y, KONG Y, AN M, et al. ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/β‑catenin pathway[J]. J Exp Clin Cancer Res, 2023, 42(1):191-201. doi:10.1186/s13046-023-02757-3.
[22]	BAO P, LI P, ZHOU X, et al. SMAR1 inhibits proliferation,EMT and Warburg effect of bladder cancer cells by suppressing the activity of the Wnt/β-catenin signaling pathway[J]. Cell Cycle, 2023, 22(2):229-241. doi:10.1080/15384101.2022.2112006.

组别	KRT17 mRNA	KRT17/β-actin
癌旁组织	0.94±0.10	0.42±0.05
膀胱癌组织	1.64±0.17	0.87±0.09
t	31.744^＊＊	39.094^＊＊

组别	KRT17 mRNA	KRT17/β-actin
癌旁组织	0.94±0.10	0.42±0.05
膀胱癌组织	1.64±0.17	0.87±0.09
t	31.744^＊＊	39.094^＊＊

细胞	KRT17 mRNA	KRT17/β-actin
SV-HUC-1	1.02±0.11	0.37±0.04
5637	1.57±0.16^a	0.54±0.06^a
UM-UC-3	1.61±0.17^a	0.51±0.07^a
T24	2.02±0.21^abc	0.84±0.09^abc
F	36.545^＊＊	51.560^＊＊

细胞	KRT17 mRNA	KRT17/β-actin
SV-HUC-1	1.02±0.11	0.37±0.04
5637	1.57±0.16^a	0.54±0.06^a
UM-UC-3	1.61±0.17^a	0.51±0.07^a
T24	2.02±0.21^abc	0.84±0.09^abc
F	36.545^＊＊	51.560^＊＊

组别	KRT17 mRNA	KRT17/β-actin
空白组	1.06±0.12	0.78±0.08
NC siRNA组	1.07±0.11	0.72±0.08
KRT17 siRNA组	0.47±0.05^ab	0.37±0.04^ab
LiCl组	1.98±0.21	1.45±0.15
KRT17 siRNA+LiCl组	1.12±0.12^cd	0.69±0.07^cd
F	99.960^＊＊	112.371^＊＊